申请人:ZENECA LIMITED
公开号:US20040009979A1
公开(公告)日:2004-01-15
The use of compounds of formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs; in formula (I), Ring C is phenyl or a carbon linked heteroaryl ring substituted as defined within; R
1
is an ortho substituent as defined within; n is 1 or 2; A-B is a linking group as defined within; R
2
and R
3
are as defined within; R
4
is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
1
使用式(I)的化合物及其盐;以及该式(I)化合物的药物可接受的体内可裂解的前药;该化合物或前药的药物可接受的盐;在式(I)中,环C是苯或被定义内取代的碳链杂环;R1是被定义内的邻位取代基;n为1或2;A-B是被定义内的连接基;R2和R3如被定义内;R4为羟基、氢、卤、氨基或甲基;用于制造用于提高温血动物如人类的PDH活性的药物。还描述了制备式(I)化合物的药物组合物、方法和过程。